Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07270783

Healthy Volunteer Study

Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Healthy Volunteer

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Pharmaron

Baltimore, Maryland, 21201, United States

About this study

Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteer subjects meeting eligibility criteria

Exclusion criteria

  • Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
  • Subjects with a history of drug and alcohol abuse
  • Subjects taking medications, over the counter or herbal remedies

Treatment and study plan

D-2570

Drug

D-2570

Placebo

Drug

Placebo

Primary outcomes

  1. Incidence of adverse events

    Time frame: From Informed Consent through study completion, an average of 48 days

    Incidence of adverse events

  2. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    Tmax

  3. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    Cmax

  4. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    t1/2

  5. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    MRT

  6. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days.

    AUC0-∞

  7. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    AUC0-t

  8. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    CL/F

  9. Result of Pharmacokinetic endpoint

    Time frame: From Randomization through study completion, an average of 20 days

    Vz/F

Sponsors and collaborators

Lead sponsor

InventisBio Co., Ltd

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2025
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.